Top Pharmaceutical Companies in London (101)
Cencora is a leading pharmaceutical solutions organization centered on improving the lives of people and animals everywhere. With 46,000+ global team members, we have the opportunity to make a positive impact on healthcare in communities everywhere. Our team members are empowered to activate their careers through a collective of tools and resources designed to support individual career interests and...
Cencora's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue has risen across multiple periods, including fiscal 2025 up about 9% to roughly $321 billion and mid‑single‑digit year‑over‑year increases in fiscal 2026 quarters. Disclosures also note Q4 FY2025 revenue of $83.7 billion, up 5.9% year over year.
Profitability: Adjusted operating income and EPS expanded, with FY2025 adjusted EPS up 16% to $16.00 and Q2 FY2026 GAAP EPS rising to $8.40 alongside a raised full‑year adjusted EPS outlook to about $17.70–$17.90. Management also indicated double‑digit adjusted operating income growth expected for FY2026.
Resilient & Sustainable Growth: Momentum spans FY2023–FY2026 to date, with revenue progressing from about $262 billion (FY2023) to $294 billion (FY2024) to $321 billion (FY2025) and continued gains in 2026. Portfolio refocusing and acquisitions in specialty care (e.g., Retina Consultants of America, OneOncology) are described as engines supporting ongoing expansion and margin mix.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health's Top Stability & Growth Strengths
Market Expansion: International partnerships across the UK, Germany, and Japan—culminating in a first Scottish agreement in 2026—are described as tripling the network in 2025 and adding nearly 70% ex‑U.S. growth in 2026. These moves indicate a materially broader geographic footprint for evidence generation.
Strategic Partnerships: Collaborations with organizations such as NHS Greater Glasgow and Clyde, Quest Diagnostics, Abbott, TailorMed, and Unicancer reflect deepening integration at the point of care and with research stakeholders. These relationships suggest expanding routes to market and data acquisition.
Product Line Growth: New offerings like Flatiron Telescope, AI‑powered oncology datasets, and an AI data‑quality/validation framework signal active investment in products and capabilities. Conference acceptances at ISPOR/ASCO/WCLC in 2026 further underscore ongoing commercialization and scientific engagement.
Shionogi B.V. (known as “Shionogi Europe”) is the European headquarters of Shionogi & Co., Ltd, a leading global research-driven pharmaceutical company based in Osaka, Japan. Since 1878, Shionogi has been striving to supply the best possible medicines to protect the health and wellbeing of the patients we serve. We are dedicated to finding innovative solutions for pressing unmet clinical needs,...
Sustainability isn’t just about tackling climate change, it represents a growing conscience around our actions and the impact they have on people, animals and planet. The personal, professional and governmental move to sustainable practice is driven by a desire to change our impact on the world, but we can’t do this without knowing the certainty of our actions. Transparency...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development...
ICON plc's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is positioned as a top-tier global CRO with significant scale and a broad geographic footprint, supported by a major acquisition that strengthened its competitive standing. Operational activity indicators and industry recognition are presented as reinforcing its ability to win and execute large, complex trials.
Profitability: Earnings and operating profit metrics are described as improving in 2024, with increases in GAAP net income, adjusted earnings per share, and adjusted EBITDA. These results suggest the business maintained solid margin performance even as quarterly revenue fluctuated.
Resilient & Sustainable Growth: A large backlog and a book-to-bill above 1.0 in 2024 are cited as providing multi-year revenue visibility and demand coverage. Continued backlog levels into 2025 are described as a stabilizing factor despite a softer near-term revenue trajectory.
Ashfield Advisory is a business unit that provides integrated advisory and consulting services to the healthcare industry, leveraging an ecosystem of specialized businesses for insight, strategy, and action.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together...
Syneos Health's Top Stability & Growth Strengths
Strong Market Position & Advantage: Company materials and third‑party recognition portray a fully integrated CRO/CCO with leadership status, including widespread involvement in recent FDA/EMA novel therapies and recognition as a leading pharmacovigilance provider.
Strategic Partnerships: Recent collaborations with Microsoft and KX are positioned to enable AI‑driven efficiencies across clinical and commercial operations, with reported improvements in cycle times supporting operational scalability.
Investor Backing & Capital Strength: The 2025 take‑private by investment groups (including Elliott and Veritas) provides financial sponsorship to pursue tech‑enabled growth and operational repositioning.
Established in 2001, Avalere Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Our team of 1,500+ experts combine their knowledge and expertise across our core disciplines—Consulting; Medical; Policy; Value, Evidence, and Access; Marketing; and Digital Experience Technology—to create the connections that make better health happen. We partner with our clients to navigate the...
Avalere Health's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Revenue expanded in consecutive years, with double‑digit growth in 2023 followed by continued albeit slower growth in 2024. Trade coverage frames 2024 as a cooling market overall, suggesting the company’s trajectory reflects resilience amid a softer cycle.
Strong Market Position & Advantage: Industry rankings place the firm consistently in the MM+M Agency 100 top 20 in 2024–2025. External awards and frequent policy visibility reinforce stature in core North American healthcare‑agency and U.S. policy/access segments.
Future-Ready Strategy: Leadership additions, a unifying rebrand, and integration of advisory, medical, access, and marketing indicate a connected commercialization model. New offerings, AI/data‑driven tools, partnerships, and the “Every Patient Possible” mission signal preparation for evolving client needs.
Helping independent pharmacies to transform into diagnostic centres.
Procter & Gamble Company is an American multi-national consumer goods corporation. P&G was founded over 180 years ago as a soap and candle company. Today, we’re the world’s largest consumer goods company and home to iconic, trusted brands, including Always®, Charmin®, Braun®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Oral B®, Pantene®, Pampers®, Tide®, and Vicks®. The design, development, growth and success...
Procter & Gamble's Top Stability & Growth Strengths
Strong Market Position & Advantage: P&G is consistently characterized as the clear industry leader with dominant positions across core categories, anchored by flagship brands like Tide, Pampers, Gillette, Crest, and Oral‑B. Multiple sources in the provided materials frame it as leading peers across home care, baby/feminine, grooming, and oral care.
Innovation-Driven Growth: The company is repeatedly recognized for leadership in product innovation and is advancing new formats and data‑driven operations to sustain momentum. References cite top‑ranked innovation in household products for multiple consecutive years and highlight launches such as new detergent formats.
Resilient & Sustainable Growth: Recent updates indicate a return to positive unit volumes with modest organic sales and EPS increases, alongside reaffirmed low single‑digit growth guidance. Dividend increases and ongoing cash returns are emphasized as continuing, underscoring a steady, durable profile.
Founded in 1997, Ergomed is a global provider of high-quality services to the biopharmaceutical industry, spanning all phases of clinical trials, post-approval pharmacovigilance, and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and Ergomed Clinical Research, a complete, global Phase I-IV clinical development and trial management services with...
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success...
At Opvia, we empower R&D, manufacturing and quality management teams to build custom process operating systems that streamline their workflows and give them a competitive edge. We work with fast-growing startups and enterprises across a range of industries, including biotech, pharma, food and beverages, engineering and medical devices, to help them digitize their processes and bring innovative products to market...
Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the...
Insulet's Top Stability & Growth Strengths
Strong Revenue Growth: Company reported accelerating revenue growth across 2024–2025 and guided continued double‑digit expansion for 2026. Quarterly updates highlighted broad‑based momentum in both U.S. and international markets.
Strong Market Position & Advantage: Omnipod leads the tubeless/patch‑pump segment and ranked No. 1 in new customer starts in the U.S. and Europe in 2024–2025, reinforcing competitive momentum. First‑to‑market AID clearance for adults with type 2 diabetes and broad CGM integrations bolster positioning.
Market Expansion: International rollouts and expansion into type 2 diabetes materially increased the addressable market and active user base. Added manufacturing capacity in Malaysia supports global demand and cost scaling.
EMJ is the number one open access destination for HCPs and Pharma professionals globally. We do this across 18 therapy areas and the pharmaceutical sector via EMJ GOLD. We use industry-leading digital tools, to meet the challenges of time-poor medical professionals with a real passion to learn and in turn to elevate the quality of healthcare globally. Our content builds trust between healthcare...
Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research, influence and information. Nearly one in two of us will get cancer in our lifetime, but we’re finding new ways to outsmart it, so that more people can live longer, better lives free from the fear of cancer. We carry out scientific research to help...
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Novartis's Top Stability & Growth Strengths
Strong Revenue Growth: Novartis shows multi-year sales expansion, with full-year results indicating continued top-line growth driven by priority brands across several therapeutic areas.
Profitability: Margins and operating income are described as strengthening, with core operating margin reaching about 40% alongside year-over-year core operating income growth.
Innovation-Driven Growth: Growth is supported by scaling priority brands and a deep pipeline with multiple high-value assets, alongside business development to add late- and mid-stage programs.
Chiltern International Limited, a contract research organization, provides clinical development, scientific services.
JUNE Medical Group is a women-owned medical devices company with offices in the UK, USA and Sweden. The company supplies selected products from leading manufacturers, and develops its own medical instruments, including the Galaxy II self retaining retractor – an extraordinary tool featuring the world’s first ever light attachment, Galaxy II™ LUX Approved Supplier: Galaxy II is already on the...
